Risk assessment of lymph node metastasis before surgery in endometrial cancer: Do we need a clinical trial for low-risk patients?
|
|
- Willa Craig
- 5 years ago
- Views:
Transcription
1 bs_bs_banner doi: /jog J. Obstet. Gynaecol. Res. Vol. 40, No. 2: , February 2014 Risk assessment of lymph node metastasis before surgery in endometrial cancer: Do we need a clinical trial for low-risk patients? Sokbom Kang 1, Yukiharu Todo 2 and Hidemichi Watari 3 1 Center for Uterine Cancer, National Cancer Center, Goyang, Korea, 2 Division of Gynecology, Hokkaido Cancer Center, and 3 Department of Obstetrics and Gynecology, Hokkaido University Graduate School of Medicine, Sapporo, Japan Abstract Due to advances of radiological imaging and tumor biomarkers, the extent of information provided by preoperative assessment is rapidly growing. The Korean Gynecologic Oncology Group (KGOG) recently proposed new preoperative criteria to identify patients at low risk for lymph node metastasis in endometrial cancer. In the multicenter study, serum carbohydrate antigen 125 levels and three magnetic resonance imaging parameters were found to be independent risk factors for nodal metastasis, and classified 53% of patients as part of a low-risk group. The false-negative predictive value (NPV) was 1.7%, and was 1.4% in the validation set. Furthermore, the KGOG low-risk criteria were validated in 319 Japanese patients with endometrial cancer. The criteria identified 181 of 319 patients as a low-risk group (51%), and three false-negative cases were found (1.9%). These results indicate that we are able to identify low-risk patients with a negligible NPV before surgery. In addition, the low false NPV implies that there is great difficulty in performing a randomized trial to determine the efficacy of routine lymphadenectomy in patients at low risk of lymph node metastasis. Based on these data, the challenges and possible solutions for developing a consensus on the optimized management of low-risk endometrial cancer will be discussed in this review. Key words: endometrial cancer, lymphadenectomy, metastasis, risk factor, staging. Introduction Although endometrial cancer is the most common gynecologic malignancy observed in Western countries, it is also well known that most patients have low-risk disease. Therefore, identifying patients who may benefit from adjuvant treatment has been a major challenge in the disease. Since Sir John Stallworthy and his colleagues reported that a substantial number of patients with early stage endometrial cancer have lymph node metastasis, 1,2 gynecologic oncologists have studied the prognostic importance of lymph node metastasis even in apparently early stage disease. Moreover, since International Federation of Gynecology and Obstetrics (FIGO) decided to adopt surgical staging including systemic lymph node dissection, routine lymphadenectomy has been the standard treatment in the field. However, because the survival benefit of routine lymphadenectomy in patients with endometrial cancer has never been proven, the clinical value of routine lymphadenectomy remains controversial. Recently, two randomized clinical trials and one systemic meta-analysis indicated that routine lymphadenectomy provided no survival benefit in endometrial cancer. 3 5 In contrast to those publications, many experts have claimed a possible benefit of routine Received: July Accepted: August Reprint request to: Dr Sokbom Kang, Center for Uterine Cancer, National Cancer Center, Goyang , Korea. sokbom@gmail.com Conflict of interest: The authors declare that there are no conflicts of interest The Authors
2 Risk assessment of lymph node metastasis lymphadenectomy in patients with unfavorable risk factors. However, there has been no debate regarding the low-risk group. This raised a question whether we can safely omit lymphadenectomy in patients without risk factors. What Is a Negligible Rate of False Positivity? Few clinical tests are free from false negativity. Therefore, to adopt a preoperative risk assessment algorithm, gynecologists must ask themselves the following question: what level of false negativity do I ask my patients to accept? In other solid tumors, a falsenegative predictive value (NPV) of 5% is commonly suggested as an acceptable rate. The National Surgical Adjuvant Breast and Bowel Project trial B-32 was an extremely large randomized phase 3 trial that set out to determine the efficacy of sentinel node biopsy (SNB) in breast cancer. 6,7 After analyzing 5611 SNB procedures, the authors concluded that the false NPV and falsenegative rate for SNB in breast cancer were 4% and 10%, respectively. 6 Its performance resulted in equivalent overall survival, disease-free survival, and regional control between the SNB arm and the full dissection arm. 7 In addition, in vulvar cancer, the recent Gynecologic Oncology Group (GOG) study reported that the SNB procedure had a false NPV of 4%. 8 Based on its the diagnostic performance, the authors concluded that SNB is a reasonable alternative to inguinal femoral lymphadenectomy in selected women with vulvar cancer. These reports indicate that a false NPV of 4% is commonly adopted as an acceptable false negativity for lymph node metastasis. In endometrial cancer, the GOG reported a landmark clinicopathological study, GOG-33. Based on the data, the authors suggested a risk grouping according to the risk of lymph node metastasis: low risk (<5%), moderate risk (5 10%) and high risk (>10%). Other experts in the field also indicated that a negligible risk for lymph node metastasis was 0 4% and that low-risk patients accounted for 75% of the entire population with the disease. 9,10 However, a comparison of the false negativity of lymph node assessment between disease sites may not be justified if the morbidity of lymphadenectomy and the consequence of neglected node metastasis differ among them. Can a false NPV of 4% safely ensure an equivalent outcome between two strategies (routine lymphadenectomy and no lymphadenectomy)? Based on the results of two recent studies, the answer is probably yes 3,4 for the following reasons. First, in the two randomized trials reporting equivalent overall survival and disease-free survival between routine lymphadenectomy and no lymphadenectomy, the observed lymph node metastasis rates in the routine lymphadenectomy groups far exceeded those of the no lymphadenectomy groups. The difference was 10% (13% vs 3%) for the Italian multicenter randomized trial 3 and 7% (8% vs 1%) for the ASTEC trial. 4 If we assume that the lymph node metastasis rates were similar between the two groups in the two trials, we find that 7 10% of false negativity did not result in a survival difference. Second, in those two trials, both low-risk and high-risk patients were included. It is therefore evident that it would be nearly impossible to observe any survival difference between the two strategy groups if only lowrisk patients are selected. Although some researchers have criticized the randomized trials, noting that they were underpowered to detect a possible survival benefit associated with routine lymphadenectomy, a recent decision analysis indicated that at least a 10% rate of neglected pelvic node metastases would be required to produce a 5% difference in the predicted overall survival between a staging and selective radiotherapy arm and a hysterectomy and radiotherapy in a high-risk group arm. 11 According to the analysis, 4% of neglected node metastases would result in a predicted difference of 1% between the two strategies. Obviously, to perform a randomized trial discriminating such a small difference in outcome may be nearly impossible without an extremely large number of subjects and vast resources. Preoperative Criteria for Identifying a Low-risk Group Even in the GOG-33 study, the authors suggested that a low-risk group existed in which routine lymphadenectomy was not recommended. 12 However, after FIGO included lymphadenectomy in the surgical staging of endometrial cancer in 1988, the procedure was endorsed as a standard surgical treatment by many practice guidelines. 13,14 However, because of the low rates of lymph node metastasis, many researchers have attempted to identify a low-risk group to avoid morbidity associated with unnecessary lymphadenectomy. The most well-known assessment algorithm was an intraoperative decision criteria proposed by researchers from the Mayo Clinic. In a review of 815 patients, Mariani et al. indicated that a low-risk group could be 2014 The Authors 323
3 S. Kang et al. defined as patients with: (i) endometrioid subtype; (ii) myometrial invasion of 50% or less; (iii) histological grade 1 2; and (iv) no intraoperative evidence of macroscopic disease. 15 The authors claimed that these patients can be treated optimally with hysterectomy only. In 2004, they revised the criteria and tumor size (diameter of 2 cm) was newly introduced. 16 After a follow-up of 1393 patients, they identified 385 (27.6%) patients that composed a low-risk group. 17 When they omitted lymphadenectomy in 305 of the 385 patients (79%), the 5-year cause-specific survival rate was 99.0%. The intraoperative algorithm was validated in two independent cohorts. In the ancillary analysis of the GOG-LAP2 trial, a false NPV was 0.8% (3/389; 95% confidence interval [CI], ) in a low-risk group identified using the Mayo criteria. 18 Another report observed a false NPV of 1.8% (2/110; 95% CI, ). However, these two studies were not based on the data from intraoperative fresh frozen pathological examination, but on the final pathological review. Thus, it is still unclear whether the intraoperative criteria will show good performance in other clinical settings. Indeed, some experts have claimed that the feasibility of making such an accurate pathological decision intraoperatively has only been proven in the Mayo Clinic. 19 Another attempt to tailor lymphadenectomy according to preoperative assessment was made by Japanese researchers. Todo et al. reported that patients with no risk factors (elevated serum carbohydrate antigen [CA]-125 level [ 70 U/mL, if aged <50 years; 28, if aged 50 years], volume index <25, serous histological type, and histological grade 3) have a low risk of pelvic lymph node metastasis (4/110 cases, 3.6%). 20 Based on these data, the authors claimed that para-aortic lymph node metastasis can be safely omitted in the low-risk group. The authors modified these algorithms into a scoring system with four risk factors (grade 3 or serous histological subtype, volume index 36, magnetic resonance imaging [MRI]-based myometrial invasion 1/2, and a high serum CA-125 level [ 70 U/ml, if aged <50 years; 28, if aged 50 years]). 21 Using the scoring system, the authors found lymph node metastasis in only 3.3% of the low-risk patients. KCOG Low-risk Criteria Although these preoperative or intra-operative risk assessment algorithms showed that the prediction of a low-risk group with a node metastasis rate of less than 4% was feasible, many gynecologists did not adopt those algorithms in clinical practice. Therefore, the Korean Gynecologic Oncology Group (KGOG) initiated a multicenter observational study to develop a well-validated guideline for identifying a low-risk group before surgery. 22 The study had two end-points. First, the criteria should identify a low-risk group with a node metastasis rate of less than 4%. Second, the criteria should identify as many low-risk patients as possible. In addition, the KGOG preferred preoperative criteria to intraoperative criteria because of several reasons: First, preoperative criteria are more helpful in patient counseling and shared decision-making. Second, preoperative criteria are more useful in future clinical trials in terms of the random allocation of enrolled subjects. Third, preoperative criteria are more convenient for surgeons because time is not spent waiting for pathological results. Using the MRI data and serum CA-125 levels of 360 patients from four institutions, a multivariate logistic regression model was developed. 22 The analysis revealed four risk factors: (i) myometrial invasion of 50% or more on MRI; (ii) lymph node enlargement on MRI; (iii) extrauterine tumor spread, including cervix, on MRI; and (iv) serum CA-125 greater than 35 U/mL. The low-risk group was characterized as patients without any of these risk factors. These criteria identified 53% of patients as a low-risk group, and the false NPV was 1.7%. When the low-risk criteria were further validated in 180 patients from two independent institutions, they identified 43% of patients as a low-risk group, and the false NPV was 1.4%. However, although the KGOG criteria were validated both internally and externally, there is a need to test whether the good performance of the criteria is reproducible in diverse clinical settings such as those with different surgical policies, imaging instruments, assay methods or pathologist s experience. Therefore, the KGOG designed a collaborative study to validate the efficacy of the KGOG low-risk model in a Japanese cohort. 23 The KGOG low-risk criteria identified 51% of patients (181/319) from two Japanese hospitals. The false NPV was 1.4% (95% CI, %). Randomized Trial in a Low-risk Group: Is It Necessary? The accumulated data showing the feasibility of pre- or intraoperative prediction may prompt us to initiate a randomized trial to assess the equality of the survival outcome between routine lymphadenectomy and no lymphadenectomy strategies. However, such a trial The Authors
4 Risk assessment of lymph node metastasis may be challenged for the following reasons. As mentioned above, the two randomized trials reported equivalent survival between the two strategies despite a 7 10% rate of neglected lymph node metastasis. 3,4 Moreover, those two trials included both low-risk and high-risk patients. Thus, it would be extremely difficult to observe any survival difference between the two strategies in low-risk patients. If a survival difference cannot be an ideal end-point, then, can improved quality of life be an alternative end-point? Unfortunately, it does not appear so. A recent meta-analysis of Cochrane Database System indicated that lymphadenectomy significantly increased systemic morbidity (relative risk, 3.7) and lymphedema formation (relative risk, 8.4). 5 Another population-based study from the Netherlands reported that women receiving lymphadenectomy reported no clinically relevant better healthrelated quality of life. 24 Therefore, neither improved survival nor improved quality of life would be expected as a merit of routine lymphadenectomy. However, although a conventional randomized trial does not appear feasible, we can plan an alternative study such as the GROINSS-VI study in vulvar cancer. 25 The GROINSS-VI study was designed as a multicenter, international, observational study investigating the safety and clinical utility of SNB in early stage vulvar cancer patients. The authors omitted inguinofemoral lymphadenectomy when the sentinel node was found to be negative. They defined the groin recurrence rate after inguinofemoral lymphadenectomy and no evidence of nodal metastasis as 2% in early stage vulvar cancer. They also defined the maximum acceptable increase in the groin recurrence rate as 6% in light of an anticipated significant decrease in treatment-related morbidity. Indeed, they observed a 2.3% groin recurrence rate and a 97% 3-year survival rate. However, there was also concern that even a 2% groin recurrence rate was high compared to the GOG historical controls. 26 Nonetheless, the truly important indicator is what patients really perceive as the maximum acceptable risk. Frequently, patients do not want to accept an additional increase of risk and are willing to accept substantial toxicity related to treatment. 27 Therefore, to design such a study scheme, a sufficient consensus on the extent of acceptable risk should be drawn from both patients and gynecologists. Conclusion In endometrial cancer, less than a 4% lymph node metastasis risk may be regarded as acceptable. Recent evidence has repeatedly suggested that to identify such a subset before or during surgery is feasible. In particular, the KGOG low-risk criteria successfully identified such a low-risk subset in both the model-developing cohort and several independent cohorts regardless of geographic differences and surgical policy. Because there is no evidence to suggest an improved survival outcome or improved quality of life in the low-risk group as a result of lymph node dissection, it should not be performed routinely in these low-risk patients. It is therefore crucially important for gynecologic oncologists to give sufficient information to their patients and involve them in shared decision-making. In the lowrisk group, lymph node dissection is recommended to be performed only in the context of clinical trials. References 1. Stallworthy JA. Surgery of endometrial cancer in the Bonney tradition. Ann R Coll Surg Engl 1971; 48: Lewis BV, Stallworthy JA, Cowdell R. Adenocarcinoma of the body of the uterus. J Obstet Gynaecol Br Commonw 1970; 77: Benedetti Panici P, Basile S, Maneschi F et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in earlystage endometrial carcinoma: Randomized clinical trial. J Natl Cancer Inst 2008; 100: Kitchener H, Swart AM, Qian Q et al. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): A randomised study. Lancet 2009; 373: May K, Bryant A, Dickinson HO et al. Lymphadenectomy for the management of endometrial cancer. Cochrane Database Syst Rev 2010; (1): CD Krag DN, Anderson SJ, Julian TB et al. Technical outcomes of sentinel-lymph-node resection and conventional axillarylymph-node dissection in patients with clinically nodenegative breast cancer: Results from the NSABP B-32 randomised phase III trial. Lancet Oncol 2007; 8: Krag DN, Anderson SJ, Julian TB et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: Overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 2010; 11: Levenback CF, Ali S, Coleman RL et al. Lymphatic mapping and sentinel lymph node biopsy in women with squamous cell carcinoma of the vulva: A Gynecologic Oncology Group study. J Clin Oncol 2012; 30: Boronow RC. Surgical staging of endometrial cancer: Evolution, evaluation, and responsible challenge a personal perspective. Gynecol Oncol 1997; 66: Sakuragi N. Emerging concept of tailored lymphadenectomy in endometrial cancer. J Gynecol Oncol 2012; 23: Naumann RW. The role of lymphadenectomy in endometrial cancer: Was the ASTEC trial doomed by design and are we destined to repeat that mistake? Gynecol Oncol 2012; 126: Creasman WT, Morrow CP, Bundy BN et al. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer 1987; 60 (8 Suppl): The Authors 325
5 S. Kang et al. 13. Greer BE, Koh WJ, Abu-Rustum N et al. Uterine neoplasms. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2009; 7: ACOG. ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: Management of endometrial cancer. Obstet Gynecol 2005; 106: Mariani A, Webb MJ, Keeney GL et al. Low-risk corpus cancer: Is lymphadenectomy or radiotherapy necessary? Am J Obstet Gynecol 2000; 182: Mariani A, Dowdy SC, Keeney GL et al. High-risk endometrial cancer subgroups: Candidates for target-based adjuvant therapy. Gynecol Oncol 2004; 95: Dowdy SC, Borah BJ, Bakkum-Gamez JN et al. Prospective assessment of survival, morbidity, and cost associated with lymphadenectomy in low-risk endometrial cancer. Gynecol Oncol 2012; 127: Milam MR, Java J, Walker JL et al. Nodal metastasis risk in endometrioid endometrial cancer. Obstet Gynecol 2012; 119 (2 Pt 1): Walker JL. Re: Clinical practice guidelines for the management of patients with endometrial cancer in France. Int J Gynecol Cancer 2012; 22: Todo Y, Sakuragi N, Nishida R et al. Combined use of magnetic resonance imaging, CA 125 assay, histologic type, and histologic grade in the prediction of lymph node metastasis in endometrial carcinoma. Am J Obstet Gynecol 2003; 188: Todo Y, Okamoto K, Hayashi M et al. A validation study of a scoring system to estimate the risk of lymph node metastasis for patients with endometrial cancer for tailoring the indication of lymphadenectomy. Gynecol Oncol 2007; 104: Kang S, Kang WD, Chung HH et al. Preoperative identification of a low-risk group for lymph node metastasis in endometrial cancer: A Korean gynecologic oncology group study. J Clin Oncol 2012; 30: Kang S, Todo Y, Odagiri T et al. A low-risk group for lymph node metastasis is accurately identified by Korean gynecologic oncology group criteria in two Japanese cohorts with endometrial cancer. Gynecol Oncol 2013; 129: van de Poll-Franse LV, Pijnenborg JM, Boll D et al. Health related quality of life and symptoms after pelvic lymphadenectomy or radiotherapy vs. no adjuvant regional treatment in early-stage endometrial carcinoma: A large populationbased study. Gynecol Oncol 2012; 127: Van der Zee AG, Oonk MH, De Hullu JA et al. Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. J Clin Oncol 2008; 26: Levenback CF. How safe is sentinel lymph node biopsy in patients with vulvar cancer? J Clin Oncol 2008; 26: de Hullu JA, Ansink AC, Tymstra T et al. What doctors and patients think about false-negative sentinel lymph nodes in vulvar cancer. J Psychosom Obstet Gynaecol 2001; 22: The Authors
Update on Sentinel Node Biopsy in Endometrial Cancer: Feasibility, Technique, Impact
Update on Sentinel Node Biopsy in Endometrial Cancer: Feasibility, Technique, Impact Bjørn Hagen, MD, PhD St Olavs Hospital Trondheim University Hospital Trondheim, Norway Endometrial Cancer (EC) The most
More informationPreoperative risk assessment for lymph node metastasis in endometrial cancer (PALME study) : results of a Korean Gynecologic Oncology Group study
Preoperative risk assessment for lymph node metastasis in endometrial cancer (PALME study) : results of a Korean Gynecologic Oncology Group study Sokbom Kang, 1 Joo-Hyun Nam, 2 Duk-Soo Bae, 3 Jae-Weon
More informationFactors predictive of myoinvasion in cases of Complex Atypical Hyperplasia diagnosed on endometrial biopsy or curettage
Factors predictive of myoinvasion in cases of Complex Atypical Hyperplasia diagnosed on endometrial biopsy or curettage Jessica Johns, MD Jeffrey Killeen, MD Robert Kim, MD Hyeong Jun Ahn, PhD None Disclosures
More informationsurgical staging g in early endometrial cancer
Risk adapted d approach to surgical staging g in early endometrial cancer Leon Massuger University Medical Centre St Radboud Nijmegen, The Netherlands Doing nodes Yes Yes Yes No No No 1957---------------------------
More informationChapter 2: Initial treatment for endometrial cancer (including histologic variant type)
Chapter 2: Initial treatment for endometrial cancer (including histologic variant type) CQ01 Which surgical techniques for hysterectomy are recommended for patients considered to be stage I preoperatively?
More informationENDOMETRIAL CANCER. Endometrial cancer is a great concern in UPDATE. For personal use only. Copyright Dowden Health Media
For mass reproduction, content licensing and permissions contact Dowden Health Media. UPDATE ENDOMETRIAL CANCER Are lymphadenectomy and external-beam radiotherapy valuable in women who have an endometrial
More informationIn this Update, I report on the latest US
UPDATE Gynecologic cancer Jason D. Wright, MD Dr. Wright is Sol Goldman Associate Professor, Chief of Division of Gynecologic Oncology, Vice Chair of Academic Affairs, Department of Obstetrics and Gynecology,
More informationMarkers HE4 and CA125 to Predict
Original Article Utility of Pelvic MRI and Tumor Markers HE4 and CA125 to Predict Depth of Myometrial Invasion and Cervical Involvement in Endometrial Cancer Narges Zamani; M.D. 1, Mitra Modares Gilani;
More informationPosition Statement on Management of the Axilla in Patients with Invasive Breast Cancer
- Official Statement - Position Statement on Management of the Axilla in Patients with Invasive Breast Cancer Sentinel lymph node (SLN) biopsy has replaced axillary lymph node dissection (ALND) for the
More informationABSTRACT AJCP /ORIGINAL ARTICLE
Assessment of the Intraoperative Consultation Service Rendered by General Pathologists in a Scenario Where a Well-Defined Decision Algorithm Is Followed Mahmoud A. Khalifa, MD, PhD, 1 Sherine Salama, MD,
More informationLaparoscopic Management of Early Stage Endometrial Cancer. B. Rabischong, M. Canis, G. Le Bouedec, C. Pomel, J.L Achard, J. Dauplat, G.
Laparoscopic Management of Early Stage Endometrial Cancer B. Rabischong, M. Canis, G. Le Bouedec, C. Pomel, J.L Achard, J. Dauplat, G. Mage Early Stage of Endometrial Cancer most of cases diagnosed (clinical
More informationRochester Minnesota Mayo Clinic
Are There Still Indications for Lymphadenectomy in Endometrial Cancer? A Mariani Mayo Clinic Rochester - MN USA Rochester Minnesota Mayo Clinic 1 Endometrial Cancer Lymphadenectomy Yes or No? Endometrial
More informationSentinel Node in Endometrial Cancer: a brief review
Sentinel Node in Endometrial Cancer: a brief review Jorge Sánchez-Lander* The rooster of my tree chases with its singing ghosts of shadows and moon specters and spirits Otilio Galíndez, Flor de mayo. Between
More informationIs Surgical Staging Necessary for Patients with Low-risk Endometrial Cancer? A Retrospective Clinical Analysis
RESEARCH ARTICLE Is Surgical Staging Necessary for Patients with Low-risk Endometrial Cancer? A Retrospective Clinical Analysis Arif Kokcu 1, Emel Kurtoglu 1 *, Handan Celik 1, Mehmet Kefeli 2, Migraci
More informationChapter 8 Adenocarcinoma
Page 80 Chapter 8 Adenocarcinoma Overview In Japan, the proportion of squamous cell carcinoma among all cervical cancers has been declining every year. In a recent survey, non-squamous cell carcinoma accounted
More informationViews and counter views The role of pelvic and para-aortic lymph node dissection in the surgical treatment of endometrial cancer: a view from the USA
The Obstetrician & Gynaecologist 10.1576/toag.11.3.199.27505 http://onlinetog.org 2009;11:199 204 Views and counter views Views and counter views The role of pelvic and para-aortic lymph node dissection
More informationInternational prospective validation trial of sentinel node biopsy in cervical cancer
Cervix cancer committee International prospective validation trial of sentinel node biopsy in cervical cancer N Abu-Rustum, F Lécuru, P Mathevet, M Plante. F Bonnetain (Statistics) G Chatellier (Clinical
More informationStaging and Treatment Update for Gynecologic Malignancies
Staging and Treatment Update for Gynecologic Malignancies Bunja Rungruang, MD Medical College of Georgia No disclosures 4 th most common new cases of cancer in women 5 th and 6 th leading cancer deaths
More informationreceive adjuvant chemotherapy
Women with high h risk early stage endometrial cancer should receive adjuvant chemotherapy Michael Friedlander The Prince of Wales Cancer Centre and Royal Hospital for Women The Prince of Wales Cancer
More informationLymph node mapping and involvement in endometrial cancer
American Journal of Clinical Cancer Research Burcu Kasap et al. American Journal of Clinical Cancer Research 2013, 1:1-10 American Journals of Clinical Cancer Research http://ivyunion.org/index.php/ajcre
More informationPreoperative assessment in endometrial cancer. Is triage for lymphadenectomy possible?
JBUON 2017; 22(1): 34-43 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Preoperative assessment in endometrial cancer. Is triage for lymphadenectomy
More informationSLN Mapping in Cervical Cancer. Memorial Sloan Kettering Cancer Center New York, USA
Lead Grou p Log SLN Mapping in Cervical Cancer Nadeem R. Abu-Rustum, M.D. Memorial Sloan Kettering Cancer Center New York, USA Conflict of Interest Disclosure Nadeem R. Abu-Rustum, M.D. I have no financial
More informationThe International Federation of Gynecology and Obstetrics (FIGO) updated the staging
Continuing Education Column Revised FIGO Staging System Hee Sug Ryu, MD Department of Obstetrics and Gynecology, Ajou University School of Medicine E - mail : hsryu@ajou.ac.kr J Korean Med Assoc 2010;
More informationInfluence of Lymphadenectomy on Survival for Early-Stage Endometrial Cancer
Influence of Lymphadenectomy on Survival for Early-Stage Endometrial Cancer Jason D. Wright, MD, Yongemei Huang, MD/PhD, William M. Burke, MD, et al. Journal Club March 16, 2016 Blaine Campbell-PGY2 Objective
More informationManagement of high risk early cervical cancer - a view of surgeon Dan DY Kim, M.D., Ph.D.
Management of high risk early cervical cancer - a view of surgeon Dan DY Kim, M.D., Ph.D. Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
More informationAn Unusual Case of Cervical Cancer with Inguinal Lymph Node Metastasis: A Case Report and Review of the Literature
Archives of Clinical and Medical Case Reports doi: 10.26502/acmcr.9655003 Volume 1, Issue 1 Case Report An Unusual Case of Cervical Cancer with Inguinal Lymph Node Metastasis: A Case Report and Review
More informationStaging. Carcinoma confined to the corpus. Carcinoma confined to the endometrium. Less than ½ myometrial invasion. Greater than ½ myometrial invasion
5 th of June 2009 Background Most common gynaecological carcinoma in developed countries Most cases are post-menopausal Increasing incidence in certain age groups Increasing death rates in the USA 5-year
More informationIntra-operative frozen section analysis of common iliac lymph nodes in patients with stage IB1 and IIA1 cervical cancer
Arch Gynecol Obstet (2012) 285:811 816 DOI 10.1007/s00404-011-2038-z GYNECOLOGIC ONCOLOGY Intra-operative frozen section analysis of common iliac lymph nodes in patients with stage IB1 and IIA1 cervical
More informationPREDICTORS OF LIMPH NODE METASTASIS IN ENDOMETRIAL CANCER
PREDICTORS OF LIMPH NODE METASTASIS IN ENDOMETRIAL CANCER 1, 1, FLORIN LAURENTIU IGNAT, ALEXANDRU IRIMIE, 1, NICOLAE COSTIN, PATRICIU ACHIMAS-CADARIU, IOAN COSMIN LISENCU 1 1 Ion Chiricuta Oncological
More informationProf. Dr. Aydın ÖZSARAN
Prof. Dr. Aydın ÖZSARAN Adenocarcinomas of the endometrium Most common gynecologic malignancy in developed countries Second most common in developing countries. Adenocarcinomas, grade 1 and 2 endometrioid
More informationComplete Pelvic Lymphadenectomy in Patients with Clinical Early, Grade I and II Endometrioid Corpus Cancer
Complete Pelvic Lymphadenectomy in Patients with Clinical Early, Grade I and II Endometrioid Corpus Cancer STELIOS FOTIOU 1, EDWARD L. TRIMBLE 3, KATERINA PAPAKONSTANTINOU 1, AGATHA KONDI-PAFITI 2, THEO
More informationRisk group criteria for tailoring adjuvant treatment in patients with endometrial cancer : a validation study of the GOG criteria
Risk group criteria for tailoring adjuvant treatment in patients with endometrial cancer : a validation study of the GOG criteria Suk-Joon Chang, MD, Hee-Sug Ryu MD Gynecologic Cancer Center Department
More informationIs Ovarian Preservation Feasible in Early-Stage Adenocarcinoma of the Cervix?
e-issn 1643-3750 DOI: 10.12659/MSM.897291 Received: 2015.12.27 Accepted: 2016.01.13 Published: 2016.02.08 Is Ovarian Preservation Feasible in Early-Stage Adenocarcinoma of the Cervix? Authors Contribution:
More informationUse of the dye guided sentinel lymph node biopsy method alone for breast cancer metastasis to avoid unnecessary axillary lymph node dissection
456 Use of the dye guided sentinel lymph node biopsy method alone for breast cancer metastasis to avoid unnecessary axillary lymph node dissection TOMOKO TAKAMARU 1, GORO KUTOMI 1, FUKINO SATOMI 1, HIROAKI
More informationManagement of Endometrial Hyperplasia
Management of Endometrial Hyperplasia I have nothing to disclose. Stefanie M. Ueda, M.D. Assistant Clinical Professor UCSF Division of Gynecologic Oncology Female Malignancies in the United States New
More informationImpact of Surgery Extent on Survival and Recurrence Rate of Stage ⅠEndometrial Adenocarcinoma
Hou et al. / Cancer Cell Research 3 (2014) 65-69 Cancer Cell Research Available at http:// http://www.cancercellresearch.org/ ISSN 2161-2609 Impact of Surgery Extent on Survival and Recurrence Rate of
More informationRadiation Therapy in Early Endometrial Cancers: Con
Radiation Therapy in Early Endometrial Cancers: Con 106 Jamie N. Bakkum-Gamez, MD Andrea Mariani, MD Karl C. Podratz, MD, PhD Introduction Endometrial cancer (EC) represents a heterogeneous spectrum of
More informationCervical Cancer: 2018 FIGO Staging
Cervical Cancer: 2018 FIGO Staging Jonathan S. Berek, MD, MMS Laurie Kraus Lacob Professor Stanford University School of Medicine Director, Stanford Women s Cancer Center Senior Scientific Advisor, Stanford
More informationSENTINEL NODES FOR EARLY VULVAL CANCER:
SENTINEL NODES FOR EARLY VULVAL CANCER: FEASIBILITY AND SAFETY IN A LOW RESOURCE SETTING LINDA ROGERS RCOG Congress 2017 None Declaration of Interests Vulval Cancer Rare 4% of all gynaecological malignancies
More informationSentinel Lymph Node Biopsy for Breast Cancer
Sentinel Lymph Node Biopsy for Breast Cancer Registrar Tutorial Adam Cichowitz Surgical Registrar The Royal Melbourne Hospital Sentinel Lymph Node Biopsy Axillary LN status important prognostic factor
More informationCytological Features of Cervical Smears in Serous Adenocarcinoma of the Endometrium
Jpn J Clin Oncol 2003;33(12)636 641 Cytological Features of Cervical Smears in Serous Adenocarcinoma of the Endometrium Yukiharu Todo, Shinichirou Minobe, Kazuhira Okamoto, Mahito Takeda, Yasuhiko Ebina,
More informationTherapeutic role of systematic lymphadenectomy in early-stage endometrial cancer: A systematic review
ONCOLOGY LETTERS 11: 3849-3857, 2016 Therapeutic role of systematic lymphadenectomy in early-stage endometrial cancer: A systematic review MEI YI LI 1,2, XIAO XIA HU 1, JIAN HONG ZHONG 3, LU LU CHEN 1
More informationPrognosis and recurrence pattern of patients with cervical carcinoma and pelvic lymph node metastasis
NJOG 2009 June-July; 4 (1): 19-24 Prognosis and recurrence pattern of patients with cervical carcinoma and pelvic lymph node metastasis Eliza Shrestha 1, Xiong Ying 1,2, Liang Li-Zhi 1,2, Zheng Min 1,2,
More informationChemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer
Find Studies About Studies Submit Studies Resources About Site Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer The safety and scientific validity of this study is
More informationTae-Wook Kong 1,2, Joo-Hyuk Son 1,2, Jiheum Paek 1,2, Yonghee Lee 1,3, Eun Ju Lee 1,4, Suk-Joon Chang 1,2, Hee-Sug Ryu 1,2
Preoperative nomogram for individualized prediction of parametrial invasion in patients with FIGO stage IB cervical cancer treated with radical hysterectomy Tae-Wook Kong 1,2, Joo-Hyuk Son 1,2, Jiheum
More informationGynecologic Cancer InterGroup Cervix Cancer Research Network. The SHAPE Trial
Gynecologic Cancer InterGroup Cervix Cancer Research Network The SHAPE Trial Comparing radical hysterectomy and pelvic node dissection against simple hysterectomy and pelvic node dissection in patients
More informationOmitting Preoperative Lymphoscintigraphy Does Not Decrease Sentinel Lymph Node Detection Rate in Vulvar Cancer
International Journal of Clinical Oncology and Cancer Research 2018; 3(3): 30-34 http://www.sciencepublishinggroup.com/j/ijcocr doi: 10.11648/j.ijcocr.20180303.13 ISSN: 2578-9503 (Print); ISSN: 2578-9511
More informationEndometrial Cancer. Saudi Gynecology Oncology Group (SGOG) Gynecological Cancer Treatment Guidelines
Saudi Gynecology Oncology Group (SGOG) Gynecological Cancer Treatment Guidelines Endometrial Cancer Emad R. Sagr, MBBS, FRCSC Consultant Gynecology Oncology Security forces Hospital, Riyadh Epidemiology
More informationUpdate on sentinel node mapping in uterine cancer: 10-year experience at Memorial Sloan Kettering Cancer Center
bs_bs_banner doi:10.1111/jog.12227 J. Obstet. Gynaecol. Res. Vol. 40, No. 2: 327 334, February 2014 Update on sentinel node mapping in uterine cancer: 10-year experience at Memorial Sloan Kettering Cancer
More informationIncidence and Clinical Outcomes of Non-endometrioid Carcinoma of Endometrium: Siriraj Hospital Experience
RESEARCH ARTICLE Incidence and Clinical Outcomes of Non-endometrioid Carcinoma of Endometrium: Siriraj Hospital Experience Atthapon Jaishuen 1, Kate Kunakornporamat 1, Boonlert Viriyapak 1, Mongkol Benjapibal
More informationAdjuvant Therapies in Endometrial Cancer. Emma Hudson
Adjuvant Therapies in Endometrial Cancer Emma Hudson Endometrial Cancer Most common gynaecological cancer Incidence increasing in Western world 1-2% cancer deaths 75% patients postmenopausal 97% epithelial
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University ijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/26054
More informationSentinel Lymph Node Biopsy Is Valuable For All Cancer. Surgery Grand Rounds Debate October 6, 2008 Joel Baumgartner
Sentinel Lymph Node Biopsy Is Valuable For All Cancer Surgery Grand Rounds Debate October 6, 2008 Joel Baumgartner History Lymphatics first described by Rasmus Bartholin in 1653 Rudolf Virchow postulated
More informationCHAPTER 4 PARAAORTIC DISSEMINATION IN ENDOMETRIAL CANCER
CHAPTER 4 PARAAORTIC DISSEMINATION IN ENDOMETRIAL CANCER New surgical guidelines (Table 1) were instituted at Mayo Clinic on January 1, 2004. A recent prospective analysis of 252 consecutive patients who
More information7. Cytoreductive surgery in endometrial cancer and uterine sarcomas
Transworld Research Network 37/661 (2), Fort P.O. Trivandrum-695 023 Kerala, India Cytoreductive Surgery in Gynecologic Oncology: A Multidisciplinary Approach, 2010: 123-151 ISBN: 978-81-7895-484-4 Editor:
More informationIs it time to consider the sentinel lymph node mapping the new standard in endometrial cancer?
Editorial Is it time to consider the sentinel lymph node mapping the new standard in endometrial cancer? Andrea Papadia, Maria Luisa Gasparri, Michael D. Mueller Department of Obstetrics and Gynecology,
More informationAbstract. Int J Gynecol Cancer 2007
Int J Gynecol Cancer 2007 Survival impact of lymph node dissection in endometrial adenocarcinoma: a surveillance, epidemiology, and end results analysis D.C. SMITH*, O.K. MACDONALD*, C.M. LEEy & D.K. GAFFNEY*
More informationManagement of Vulvar Cancer: How to Handle Close Margins?
Management of Vulvar Cancer: How to Handle Close Margins? Sven Mahner, MD Department of Gynecology and Obstetrics University of Munich AGO Study Group Munich, Germany Surgical Resection of Vulvar Cancer
More informationA prediction model of survival for patients with bone metastasis from uterine corpus cancer
JJCO Japanese Journal of Clinical Oncology Japanese Journal of Clinical Oncology, 2016, 46(11) 973 978 doi: 10.1093/jjco/hyw120 Advance Access Publication Date: 21 September 2016 Original Article Original
More informationRelapse Patterns and Outcomes Following Recurrence of Endometrial Cancer in Northern Thai Women
DOI:http://dx.doi.org/10.7314/APJCP.2015.16.9.3861 Relapse Patterns and Outcomes Following Recurrence of Endometrial Cancer in Northern Thai Women RESEARCH ARTICLE Relapse Patterns and Outcomes Following
More informationThe Role of Sentinel Lymph Node Biopsy and Axillary Dissection
The Role of Sentinel Lymph Node Biopsy and Axillary Dissection Henry Mark Kuerer, MD, PhD, FACS Department of Surgical Oncology University of Texas MD Anderson Cancer Center SLN Biopsy Revolutionized surgical
More informationMichael G. Kelly, MD Gynecologic Oncologist University of Colorado Cancer Center
Michael G. Kelly, MD Gynecologic Oncologist University of Colorado Cancer Center 50 yo healthy postmenopausal female with BMI = 35 with screening PAP smear = AGUS. What is the next step? (1) Colposcopy
More informationOriginal Article Systematic lymphadenectomy for survival in patients with early-stage endometrial cancer: a meta-analysis
Int J Clin Exp Med 2017;10(3):5029-5037 www.ijcem.com /ISSN:1940-5901/IJCEM0040649 Original Article Systematic lymphadenectomy for survival in patients with early-stage endometrial cancer: a meta-analysis
More informationLocally advanced disease & challenges in management
Gynecologic Cancer InterGroup Cervix Cancer Research Network Cervix Cancer Education Symposium, February 2018 Locally advanced disease & challenges in management Carien Creutzberg Radiation Oncology, Leiden
More informationCharacteristics and prognosis of coexisting adnexa malignancy with endometrial cancer: a single institution review of 51 cases
Arch Gynecol Obstet (2011) 283:1133 1137 DOI 10.1007/s00404-010-1574-2 GYNECOLOGIC ONNCOLOGY Characteristics and prognosis of coexisting adnexa malignancy with endometrial cancer: a single institution
More informationLymphovascular Invasion Is a Significant Predictor for Distant Recurrence in Patients With Early-Stage Endometrial Endometrioid Adenocarcinoma
Anatomic Pathology / LVI in Endometrial Cancer Lymphovascular Invasion Is a Significant Predictor for Distant Recurrence in Patients With Early-Stage Endometrial Endometrioid Adenocarcinoma Sharon Nofech-Mozes,
More informationAbscopal Effect of Radiation on Toruliform Para-aortic Lymph Node Metastases of Advanced Uterine Cervical Carcinoma A Case Report
Abscopal Effect of Radiation on Toruliform Para-aortic Lymph Node Metastases of Advanced Uterine Cervical Carcinoma A Case Report MAMIKO TAKAYA 1, YUZURU NIIBE 1, SHINPEI TSUNODA 2, TOSHIKO JOBO 2, MANAMI
More informationPreoperative serum CA125: a useful marker for surgical management of endometrial cancer
Jiang et al. BMC Cancer (2015) 15:396 DOI 10.1186/s12885-015-1260-7 RESEARCH ARTICLE Open Access Preoperative serum CA125: a useful marker for surgical management of endometrial cancer Tao Jiang *, Ling
More informationPost operative Radiotherapy in Carcinoma Endometrium - KMIO Experience (A Retrospective Study)
Post operative Radiotherapy in Carcinoma Endometrium - KMIO Experience (A Retrospective Study) Sridhar.P, M.D. 1, Sruthi.K, M.D. 2, Naveen.T, M.D. 3, Siddanna.R.P, M.D. 4 Department of Radiation Oncology,
More informationEGFR expression is associated with groin node metastases in vulvar cancer, but does not improve their prediction
Gynecologic Oncology 104 (2007) 109 113 www.elsevier.com/locate/ygyno EGFR expression is associated with groin node metastases in vulvar cancer, but does not improve their prediction M.H.M. Oonk a, G.H.
More informationSentinel node biopsy in breast cancer patients treated with neoadjuvant chemotherapy
ONCOLOGY REPORTS 15: 927-931, 2005 927 Sentinel node biopsy in breast cancer patients treated with neoadjuvant chemotherapy YOSUKE TANAKA 1, HIRONORI MAEDA 2, YASUHIRO OGAWA 3, AKIHITO NISHIOKA 3, SATOSHI
More informationGynecologic Cancer Surveillance and Survivorship: Informing Practice and Policy
Gynecologic Cancer Surveillance and Survivorship: Informing Practice and Policy Stephanie Yap, M.D. University Gynecologic Oncology Northside Cancer Institute Our Learning Objectives Review survival rates,
More informationWhat is endometrial cancer?
Uterine cancer What is endometrial cancer? Endometrial cancer is the growth of abnormal cells in the lining of the uterus. The lining is called the endometrium. Endometrial cancer usually occurs in women
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): October 1, 2014 Most Recent Review Date (Revised): May 20, 2014 Effective Date: October 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT
More informationIs Sentinel Node Biopsy Practical?
Breast Cancer Is Sentinel Node Biopsy Practical? Benefits and Limitations JMAJ 45(10): 444 448, 2002 Shigeru IMOTO *1, Satoshi EBIHARA *2 and Noriyuki MORIYAMA *3 *1 Breast Surgery Division, National Cancer
More informationLoco-Regional Management After Neoadjuvant Chemotherapy
1 Loco-Regional Management After Neoadjuvant Chemotherapy Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health Cancer Center at Orlando Health Professor of Surgery,
More informationManagement of the Axilla at Initial Surgery Manejo da Axila em Cirurgia Inicial
DISCIPLINA DE MASTOLOGIA ESCOLA PAULISTA DE MEDICINA UNIVERSIDADE FEDERAL DE SÃO PAULO Management of the Axilla at Initial Surgery Manejo da Axila em Cirurgia Inicial Disciplina de Mastologia Prof. Dr.
More informationReview Article Selective Inguinal Lymphadenectomy in the Treatment of Invasive Squamous Cell Carcinoma of the Vulva
Hindawi Publishing Corporation International Journal of Surgical Oncology Volume 2011, Article ID 284374, 6 pages doi:10.1155/2011/284374 Review Article Selective Inguinal Lymphadenectomy in the Treatment
More informationComparison of intra-operative gamma probe detection with postoperative SPECT/CT of sentinel nodes related to the ovary.
Journal of Nuclear Medicine, published on October 13, 2016 as doi:10.2967/jnumed.116.183426 Comparison of intra-operative gamma probe detection with postoperative SPECT/CT of sentinel nodes related to
More informationPROTOCOL SENTINEL NODE BIOPSY (NON OPERATIVE) BREAST CANCER - PATHOLOGY ASSESSMENT
PROTOCOL SENTINEL NODE BIOPSY (NON OPERATIVE) BREAST CANCER - PATHOLOGY ASSESSMENT Author: Dr Sally Ann Hales On behalf of the Breast and pathology CNGs Written: March 2005 Reviewed by CNG: June 2009 &
More informationThe Challenge of Individualizing Loco-Regional Treatments for Patients with Localized Breast Cancer
The Challenge of Individualizing Loco-Regional Treatments for Patients with Localized Breast Cancer Le défi des traitements locorégionaux individualisés pour les patientes présentant un cancer du sein
More informationIndex. B Bilateral salpingo-oophorectomy (BSO), 69
A Advanced stage endometrial cancer diagnosis, 92 lymph node metastasis, 92 multivariate analysis, 92 myometrial invasion, 92 prognostic factors FIGO stage, 94 histological grade, 94, 95 histologic cell
More informationUTERINE SARCOMAS CURRENT THERAPEUTIC OPTIONS
Review Journal of Translational Medicine and Research, volume 19, no. 1-2, 2014 UTERINE SARCOMAS CURRENT THERAPEUTIC OPTIONS N. Bacalbaæa 1, A. Traistaru 2, I. Bãlescu 3 1 Carol Davila University of Medicine
More informationNew NCCN Guidelines for Vulvar Cancer
New NCCN Guidelines for Vulvar Cancer Benjamin E. Greer, MD Fred Hutchinson Cancer Research Center/ Seattle Cancer Care Alliance Vulvar Cancer Objectives: 1) Overview of vulvar carcinoma and FIGO staging.
More informationBecause ovarian cancer is usually diagnosed
OVARIAN CANCER Recent studies shed light on early detection of but it s not a green light for routine screening. Until promising avenues of research lead further, refer women who have an adnexal mass,
More informationHemoglobin A1c and the relationship to stage and grade of endometrial cancer
DOI 10.1007/s00404-012-2455-7 GYNECOLOGIC ONCOLOGY Hemoglobin A1c and the relationship to stage and grade of endometrial cancer Erin E. Stevens Sarah Yu Melanie Van Sise Tana Shah Pradhan Vanessa Lee Michael
More informationRetrospective evaluation of clinical and pathological features, as well as diagnostic and treatment protocols of primary vaginal malignancy
ORIGINAL PAPER / GYNECOLOGY Ginekologia Polska 2016, vol. 87, no. 8, 541 545 Copyright 2016 Via Medica ISSN 0017 0011 DOI: 10.5603/GP.2016.0041 Retrospective evaluation of clinical and pathological features,
More informationLoco-Regional Management After Neoadjuvant Chemotherapy
1 Loco-Regional Management After Neoadjuvant Chemotherapy Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health Cancer Center at Orlando Health Professor of Surgery,
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER CERVIX
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER CERVIX Site Group: Gynecology Cervix Author: Dr. Stephane Laframboise 1. INTRODUCTION 3 2. PREVENTION 3 3. SCREENING AND
More information2016 Uterine Cancer Annual Report
2016 Uterine Cancer Annual Report Overview At Carolinas HealthCare System s Levine Cancer Institute, we offer comprehensive care focused on using the latest technology and innovative techniques in the
More informationAdjuvant Radiotherapy in Endometrial Carcinoma David T. Shaeffer and Marcus E. Randall. doi: /theoncologist
Adjuvant Radiotherapy in Endometrial Carcinoma David T. Shaeffer and Marcus E. Randall The Oncologist 2005, 10:623-631. doi: 10.1634/theoncologist.10-8-623 The online version of this article, along with
More informationTherapeutic Role of Lymph Node Resection in Endometrioid Corpus Cancer. BACKGROUND. The purpose of the current study was to determine the potential
1823 Therapeutic Role of Lymph Node Resection in Endometrioid Corpus Cancer A Study of 12,333 Patients John K. Chan, MD 1 Michael K. Cheung, BA 1 Warner K. Huh, MD 3 Kathryn Osann, PhD 4 Amreen Husain,
More informationFactors associated with parametrial involvement in patients with stage IB1 cervical cancer: who is suitable for less radical surgery?
Original Article Obstet Gynecol Sci 2018;61(1):88-94 https://doi.org/10.5468/ogs.2018.61.1.88 pissn 2287-8572 eissn 2287-8580 Factors associated with parametrial involvement in patients with stage IB1
More informationAdvances in Breast Surgery. Catherine Campo, D.O. Breast Surgeon Meridian Health System April 17, 2015
Advances in Breast Surgery Catherine Campo, D.O. Breast Surgeon Meridian Health System April 17, 2015 Objectives Understand the surgical treatment of breast cancer Be able to determine when a lumpectomy
More informationAdjuvant radiotherapy and survival outcomes in early-stage endometrial cancer: A multi-institutional analysis of 608 women
Gynecologic Oncology 103 (2006) 661 666 www.elsevier.com/locate/ygyno Adjuvant radiotherapy and survival outcomes in early-stage endometrial cancer: A multi-institutional analysis of 608 women O. Kenneth
More informationSentinel Node Biopsy. Is There Any Role for Axillary Dissection? JCCNB Nov 20, Stephen B. Edge, MD
Sentinel Node Biopsy Is There Any Role for Axillary Dissection? JCCNB Nov 20, 2010 Tokyo, Japan Stephen B. Edge, MD Roswell Park Cancer Institute University at Buffalo Buffalo, NY USA SNB with Clinically
More informationNew Cancer Cases By Site Breast 28% Lung 14% Colo-Rectal 10% Uterus 6% Thyroid 5% Lymphoma 4% Ovary 3%
Uterine Malignancy New Cancer Cases By Site 2010 Breast 28% Lung 14% Colo-Rectal 10% Uterus 6% Thyroid 5% Lymphoma 4% Ovary 3% Cancer Deaths By Site 2010 Lung 26% Breast 15% Colo-Rectal 9% Pancreas 7%
More informationRole of Laparoscopic Surgery in the Management of Endometrial Cancer
559 Role of Laparoscopic Surgery in the Management of Endometrial Cancer Meaghan Tenney, MD, and Joan L. Walker, MD, Oklahoma City, Oklahoma Key Words Uterine cancer, neoplasm, endometrial cancer, laparoscopy,
More informationPublic Statement: Medical Policy Statement: Limits: Medical Policy Title: OVA1, Detection of Ovarian Cancer. ARBenefits Approval: 10/26/2011
ARBenefits Approval: 10/26/2011 Effective Date: 01/01/2012 Revision Date: 08/21/2013 Medical Policy Title: OVA1, Detection of Ovarian Cancer Document: ARB0295:02 Administered by: Public Statement: The
More informationDesmoplastic Melanoma: Surgical Management and Adjuvant Therapy
Desmoplastic Melanoma: Surgical Management and Adjuvant Therapy Dale Han, MD Assistant Professor Department of Surgery Section of Surgical Oncology No disclosures Background Desmoplastic melanoma (DM)
More information